China Oncology ›› 2024, Vol. 34 ›› Issue (12): 1144-1163.doi: 10.19401/j.cnki.1007-3639.2024.12.009
Expert Committee on Pathology of Chinese Research Hospital Association , Professional Committee on Tumor Pathology of Shanghai Anticancer Association
Received:
2024-11-10
Online:
2024-12-30
Published:
2025-01-21
Share article
Expert Committee on Pathology of Chinese Research Hospital Association , Professional Committee on Tumor Pathology of Shanghai Anticancer Association . Practice guideline for the histopathological diagnosis of mesothelioma (2025 version)[J]. China Oncology, 2024, 34(12): 1144-1163.
"
1. 活检标本 |
---|
标本类型:_________ |
肿瘤部位:_________ |
□ _________侧胸膜 |
□ 腹膜 |
□ 其他,_________ |
送检组织大小:_________ |
组织学类型(WHO)和疾病编码(ICD):_________ |
□ 上皮样间皮瘤 ICD-O编码9052/3 ICD-11编码XH0VP5 |
□ 肉瘤样间皮瘤 ICD-O编码9051/3 ICD-11编码XH54S8 |
□ 促纤维性间皮瘤 ICD-O编码9051/3 ICD-11编码XH54S8 |
□ 双相性间皮瘤 ICD-O编码9053/3 ICD-11编码XH1DX8 |
□ 原位间皮瘤 ICD-O编码9050/2 |
肿瘤级别:_________(仅适用于胸膜上皮样间皮瘤) |
□ 低级别 □ 高级别 |
组织学形态:_________;_________;_________ |
□ 组织结构:(不需要给出百分比) |
□ 细胞形态:_________ |
□ 间质形态:_________ |
辅助检测:_________ |
① 免疫组织化学检测:_________(BAP1,MTAP) |
② 分子检测:_________(FISH检测CDKN2A) |
2. 手术标本 |
标本类型:_________ |
肿瘤部位:_________ |
□ _________侧胸膜 |
□腹膜 |
□ 其他,_________ |
肿瘤病灶:_________ |
□ 弥漫性 |
□ 局限性 |
□ 不能判断 |
肿瘤大小:_________ |
□ _________cm × _________cm× _________cm(长径×纵径×横径) |
□ 最大径_________cm,或总体积:_________cm3 |
□ 最大径范围_________cm ~_________cm |
组织学类型(WHO)和疾病编码(ICD):_________ |
□ 上皮样间皮瘤 ICD-O编码9052/3 ICD-11编码XH0VP5 |
□ 肉瘤样间皮瘤 ICD-O编码9051/3 ICD-11编码XH54S8 |
□ 促纤维性间皮瘤 ICD-O编码9051/3 ICD-11编码XH54S8 |
□ 双相性间皮瘤 ICD-O编码9053/3 ICD-11编码XH1DX8 |
□ 原位间皮瘤 ICD-O编码9050/2 |
肿瘤级别:_________(仅适用于胸膜上皮样间皮瘤) |
□ 低级别 □ 高级别 |
组织学形态:_________ |
□ 组织结构:_________(列出主要结构类型和各种结构百分比) |
□ 细胞形态:_________ |
□ 间质形态:_________ |
浸润范围:_________ |
切缘情况:_________ |
淋巴结:_________ |
pTNM(第8版UICC/AJCC):_________(适用于胸膜间皮瘤) |
腹腔癌症指数(PCI):_________(可用于腹膜间皮瘤) |
辅助检测:_________ |
① 免疫组织化学:_________(BAP1,MTAP) |
② 分子检测:_________(FISH检测CDKN2A) |
[1] | ZHAI Y R, HUI Z G, CHEN W Q, et al. The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016-2030[J]. Transl Lung Cancer Res, 2022, 11(12): 2403-2411. |
[2] | 陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版)[J]. 中华医学杂志, 2022, 102(10): 697-703. |
CHEN Y L, YANG K H, WANG X Q, et al. Guiding principles for formulating/revising clinical diagnosis and treatment guidelines in China (2022 edition)[J]. Natl Med J China, 2022, 102(10): 697-703. | |
[3] |
CHEN Y L, YANG K H, MARUŠIC A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement[J]. Ann Intern Med, 2017, 166(2): 128-132.
doi: 10.7326/M16-1565 pmid: 27893062 |
[4] |
O’NEIL J D, ROS P R, STORM B L, et al. Cystic mesothelioma of the peritoneum[J]. Radiology, 1989, 170(2): 333-337.
pmid: 2643136 |
[5] |
SUN M, ZHAO L, WENG LAO I, et al. Well-differentiated papillary mesothelioma: a 17-year single institution experience with a series of 75 cases[J]. Ann Diagn Pathol, 2019, 38: 43-50.
doi: S1092-9134(18)30320-4 pmid: 30419426 |
[6] |
DRUT R, QUIJANO G. Multilocular mesothelial inclusion cysts (so-called benign multicystic mesothelioma) of pericardium[J]. Histopathology, 1999, 34(5): 472-474.
pmid: 10231425 |
[7] | CHURG A, GALATEAU-SALLE F. Well differentiated papillary mesothelial tumor: a new name and new problems[J]. Mod Pathol, 2022, 35(10): 1327-1333. |
[8] | WHO Classification of Tumours Editorial Board. WHO classification of tumours: thoracic tumours/urinary and male genital tumours/female genital tumours[M]. 5th ed. Lyon, France: International Agency for Research on Cancer; 2021. |
[9] |
SAUTER J L, DACIC S, GALATEAU-SALLE F, et al. The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification[J]. J Thorac Oncol, 2022, 17(5): 608-622.
doi: 10.1016/j.jtho.2021.12.014 pmid: 35026477 |
[10] | World Health Organization. International classification of diseases for oncology (ICD-O), 3rd ed., 1st revision. Geneva, Switzerland: World Health Organization. 2013y[EB/OL]. https://iris.who.int/handle/10665/96612. |
[11] | World Health Organization. ICD-11 2022 release Geneva, Switzerland: World Health Organization, 2022. https://www.who.int/news/item/11-02-2022-icd-11-2022-release. |
[12] |
GARIAZZO C, GASPARRINI A, MARINACCIO A. Asbestos consumption and malignant mesothelioma mortality trends in the major user countries[J]. Ann Glob Health, 2023, 89(1): 11.
doi: 10.5334/aogh.4012 pmid: 36819965 |
[13] |
METINTAS M, HILLERDAL G, METINTAS S. Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort[J]. Eur Respir J, 1999, 13(3): 523-526.
pmid: 10232420 |
[14] | FARIOLI A, OTTONE M, MORGANTI A G, et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database[J]. Cancer Med, 2016, 5(5): 950-959. |
[15] | DONALDSON K, POLAND C A, MURPHY F A, et al. Pulmonary toxicity of carbon nanotubes and asbestos-similarities and differences[J]. Adv Drug Deliv Rev, 2013, 65(15): 2078-2086. |
[16] |
TESTA J R, CHEUNG M, PEI J M, et al. Germline BAP1 mutations predispose to malignant mesothelioma[J]. Nat Genet, 2011, 43(10): 1022-1025.
doi: 10.1038/ng.912 pmid: 21874000 |
[17] |
ATTANOOS R L, CHURG A, GALATEAU-SALLE F, et al. Malignant mesothelioma and its non-asbestos causes[J]. Arch Pathol Lab Med, 2018, 142(6): 753-760.
doi: 10.5858/arpa.2017-0365-RA pmid: 29480760 |
[18] |
MEZEI G, CHANG E T, MOWAT F S, et al. Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis[J]. Ann Epidemiol, 2017, 27(5): 348-359.e11.
doi: S1047-2797(17)30287-9 pmid: 28527639 |
[19] | MOOLGAVKAR S H, MEZA R, TURIM J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005[J]. Cancer Causes Control, 2009, 20(6): 935-944. |
[20] |
ALLEN T C, CAGLE P T, CHURG A M, et al. Localized malignant mesothelioma[J]. Am J Surg Pathol, 2005, 29(7): 866-873.
doi: 10.1097/01.pas.0000165529.78945.dc pmid: 15958850 |
[21] |
MALPICA A, EUSCHER E D, MARQUES-PIUBELLI M L, et al. Localized malignant peritoneal mesothelioma (LMPeM) in women: a clinicopathologic study of 18 cases[J]. Am J Surg Pathol, 2022, 46(10): 1352-1363.
doi: 10.1097/PAS.0000000000001924 pmid: 35713639 |
[22] | MARCHEVSKY A M, KHOOR A, WALTS A E, et al. Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel[J]. Mod Pathol, 2020, 33(2): 281-296. |
[23] | ZHANG Y, PANG M J. Unveiling the mystery: a rare case of localized malignant pericardial mesothelioma-case report[J]. Front Oncol, 2024, 14: 1342748. |
[24] | ESPINAL-WITTER R, SERVAIS E L, KLIMSTRA D S, et al. Localized intrapancreatic malignant mesothelioma: a rare entity that may be confused with other pancreatic neoplasms[J]. Virchows Arch, 2010, 456(4): 455-461. |
[25] |
JIANG Y Q, CAI Y, XU X P, et al. A rare malignant mesothelioma of the tunica vaginalis testis: a case report[J]. Oncol Lett, 2024, 27(4): 172.
doi: 10.3892/ol.2024.14305 pmid: 38455661 |
[26] | HUNG Y P, DONG F, DUBUC A M, et al. Molecular characterization of localized pleural mesothelioma[J]. Mod Pathol, 2020, 33(2): 271-280. |
[27] |
NICHOLSON A G, SAUTER J L, NOWAK A K, et al. EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach[J]. J Thorac Oncol, 2020, 15(1): 29-49.
doi: S1556-0864(19)33232-0 pmid: 31546041 |
[28] |
HUSAIN A N, CHAPEL D B, ATTANOOS R, et al. Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the international mesothelioma interest group[J]. Arch Pathol Lab Med, 2024, 148(11): 1251-1271.
doi: 10.5858/arpa.2023-0304-RA pmid: 38586983 |
[29] | KADOTA K, SUZUKI K, COLOVOS C, et al. A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma[J]. Mod Pathol, 2012, 25(2): 260-271. |
[30] | SCHULTE J J, HUSAIN A N. Updates on grading mesothelioma[J]. Histopathology, 2024, 84(1): 153-162. |
[31] | ORDÓÑEZ N G. Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases[J]. Mod Pathol, 2006, 19(3): 373-383. |
[32] | ORDÓÑEZ N G. Pleomorphic mesothelioma: report of 10 cases[J]. Mod Pathol, 2012, 25(7): 1011-1022. |
[33] | LIU S, STAATS P, LEE M, et al. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients[J]. Pathology, 2014, 46(7): 604-609. |
[34] |
OYAMA T, GOTO T, AMEMIYA K. Mixed micropapillary patterns found in malignant pleural mesothelioma with possibly worsened prognostic implication[J]. Thorac Cancer, 2022, 13(7): 1098-1099.
doi: 10.1111/1759-7714.14364 pmid: 35212151 |
[35] | ROSEN L E, KARRISON T, ANANTHANARAYANAN V, et al. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study[J]. Mod Pathol, 2018, 31(4): 598-606. |
[36] |
ALCHAMI F S, ATTANOOS R L, BAMBER A R. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma[J]. J Clin Pathol, 2017, 70(2): 179-182.
doi: 10.1136/jclinpath-2016-203993 pmid: 27798081 |
[37] | KLEBE S, BROWNLEE N A, MAHAR A, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases[J]. Mod Pathol, 2010, 23(3): 470-479. |
[38] | 刘绮颖, 陈庆明, 喻林, 等. 肉瘤样恶性间皮瘤的临床病理分析[J]. 中华病理学杂志, 2014, 43(6): 364-369. |
LIU Q Y, CHEN Q M, YU L, et al. Sarcomatoid malignant mesothelioma: A clinicopathologic and immunohistochemical analysis of 22 cases[J]. Chin J Pathol, 2014, 43(6): 364-369. | |
[39] | GALATEAU-SALLÉ F, ATTANOOS R, GIBBS A R, et al. Lymphohistiocytoid variant of malignant mesothelioma of the pleura: a series of 22 cases[J]. Am J Surg Pathol, 2007, 31(5): 711-716. |
[40] |
CANTIN R, AL-JABI M, MCCAUGHEY W T. Desmoplastic diffuse mesothelioma[J]. Am J Surg Pathol, 1982, 6(3): 215-222.
pmid: 7102900 |
[41] | KLEBE S, MAHAR A, HENDERSON D W, et al. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review[J]. Mod Pathol, 2008, 21(9): 1084-1094. |
[42] | DACIC S, STANG N L, HUSAIN A, et al. Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas[J]. Mod Pathol, 2020, 33(2): 255-262. |
[43] |
SALLE F G, LE STANG N, TIRODE F, et al. Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the international mesothelioma panel from the MESOPATH reference center[J]. J Thorac Oncol, 2020, 15(6): 1037-1053.
doi: S1556-0864(20)30174-X pmid: 32165206 |
[44] | FORTAREZZA F, PEZZUTO F, MANIGLIO S, et al. Adverse prognostic impact of transitional and pleomorphic patterns in pleural nonepithelioid mesothelioma: insights from comprehensive analysis and reticulin stain[J]. Arch Pathol Lab Med, 2024. |
[45] |
GALATEAU SALLE F, STANG N L, NICHOLSON A G, et al. New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center[J]. J Thorac Oncol, 2018, 13(8): 1189-1203.
doi: S1556-0864(18)30551-3 pmid: 29723687 |
[46] | FOREST F, PATOIR A, DAL COL P, et al. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications[J]. Pathology, 2018, 50(6): 635-641. |
[47] |
ZHANG Y Z, BRAMBILLA C, MOLYNEAUX P L, et al. Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade[J]. Histopathology, 2020, 77(3): 423-436.
doi: 10.1111/his.14127 pmid: 32333813 |
[48] |
ZHANG Y Z, BRAMBILLA C, MOLYNEAUX P L, et al. Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases[J]. Am J Surg Pathol, 2020, 44(3): 347-356.
doi: 10.1097/PAS.0000000000001416 pmid: 32045387 |
[49] |
WANG Q, XU C W, WANG W X, et al. Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma[J]. Thorac Cancer, 2023, 14(26): 2715-2731.
doi: 10.1111/1759-7714.15022 pmid: 37461124 |
[50] | POPAT S, BAAS P, FAIVRE-FINN C, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(2): 129-142. |
[51] |
TÜRK İ, FINDIK G, ÇETIN M, et al. Importance of histopathological grading for treatment selection in malignant mesothelioma[J]. Thorac Cardiovasc Surg, 2023, 71(6): 497-503.
doi: 10.1055/s-0043-1761209 pmid: 36736368 |
[52] |
SCHULTE J J, CHAPEL D B, ATTANOOS R, et al. Comparison of nuclear grade, necrosis, and histologic subtype between biopsy and resection in pleural malignant mesothelioma: an international multi-institutional analysis[J]. Am J Clin Pathol, 2021, 156(6): 989-999.
doi: 10.1093/ajcp/aqab054 pmid: 33978147 |
[53] |
VALENTE K, BLACKHAM A U, LEVINE E, et al. A histomorphologic grading system that predicts overall survival in diffuse malignant peritoneal mesothelioma with epithelioid subtype[J]. Am J Surg Pathol, 2016, 40(9): 1243-1248.
doi: 10.1097/PAS.0000000000000696 pmid: 27438989 |
[54] |
PEZZUTO F, VIMERCATI L, FORTAREZZA F, et al. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report[J]. Diagn Pathol, 2021, 16(1): 64.
doi: 10.1186/s13000-021-01125-z pmid: 34294087 |
[55] | CHAPEL D B, SCHULTE J J, ABSENGER G, et al. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases[J]. Mod Pathol, 2021, 34(2): 380-395. |
[56] | FUCHS T L, CHOU A, AKSOY Y, et al. A critical assessment of current grading schemes for diffuse pleural mesothelioma with a proposal for a novel mesothelioma weighted grading scheme (MWGS)[J]. Am J Surg Pathol, 2022, 46(6): 774-785. |
[57] | AKSOY Y, CHOU A, MAHJOUB M, et al. A novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma[J]. Pathology, 2023, 55(4): 449-455. |
[58] | GALEANO B, SMITH C J, YI E S, et al. Ki-67 proliferation index is associated with tumor grade and survival in pleural epithelioid mesotheliomas[J]. Am J Surg Pathol, 2024, 48(5): 615-622. |
[59] |
HUNG Y P, CHIRIEAC L R. Molecular and immunohistochemical testing in mesothelioma and other mesothelial lesions[J]. Arch Pathol Lab Med, 2024, 148(5): e77-e89.
doi: 10.5858/arpa.2023-0213-RA pmid: 38190277 |
[60] |
NASO J R, TSUJI S, CHURG A. HEG1 is a highly specific and sensitive marker of epithelioid malignant mesothelioma[J]. Am J Surg Pathol, 2020, 44(8): 1143-1148.
doi: 10.1097/PAS.0000000000001469 pmid: 32205484 |
[61] | NAKAGIRI T, AMATYA V J, KUSHITANI K, et al. SPARC is a novel positive immunohistochemical marker of epithelioid mesothelioma to differentiate it from lung adenocarcinoma and/or squamous cell carcinoma[J]. Am J Surg Pathol, 2024, 48(2): 140-149. |
[62] |
KIMURA N, HASEGAWA M, HIROSHIMA K. SMARCB1/INI1/BAF47- deficient pleural malignant mesothelioma with rhabdoid features[J]. Pathol Int, 2018, 68(2): 128-132.
doi: 10.1111/pin.12623 pmid: 29316066 |
[63] |
HUNG Y P, DONG F, WATKINS J C, et al. Identification of ALK rearrangements in malignant peritoneal mesothelioma[J]. JAMA Oncol, 2018, 4(2): 235-238.
doi: 10.1001/jamaoncol.2017.2918 pmid: 28910456 |
[64] |
XING D Y, BANET N, SHARMA R, et al. Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study[J]. Hum Pathol, 2018, 72: 160-166.
doi: S0046-8177(17)30463-X pmid: 29241740 |
[65] |
BERG K B, CHURG A. GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung[J]. Am J Surg Pathol, 2017, 41(9): 1221-1225.
doi: 10.1097/PAS.0000000000000825 pmid: 28614203 |
[66] | TERRA S B S P, RODEN A C, AUBRY M C, et al. Utility of immunohistochemistry for MUC4 and GATA3 to aid in the distinction of pleural sarcomatoid mesothelioma from pulmonary sarcomatoid carcinoma[J]. Arch Pathol Lab Med, 2021, 145(2): 208-213. |
[67] | TERRA S, RODEN A C, YI E S, et al. Loss of methylthioadenosine phosphorylase by immunohistochemistry is common in pulmonary sarcomatoid carcinoma and sarcomatoid mesothelioma[J]. Am J Clin Pathol, 2022, 157(1): 33-39. |
[68] | RIENZO A D, CHIRIEAC L R, HUNG Y P, et al. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma[J]. J Pathol, 2021, 253(1): 68-79. |
[69] | CHAPEL D B, HORNICK J L, BARLOW J, et al. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma[J]. Mod Pathol, 2022, 35(10): 1383-1397. |
[70] |
PETERS S, SCHERPEREEL A, CORNELISSEN R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743[J]. Ann Oncol, 2022, 33(5): 488-499.
doi: 10.1016/j.annonc.2022.01.074 pmid: 35124183 |
[71] |
CHAPEL D B, STEWART R, FURTADO L V, et al. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays[J]. Hum Pathol, 2019, 87: 11-17.
doi: S0046-8177(19)30017-6 pmid: 30794891 |
[72] | BRCIC L, KLIKOVITS T, MEGYESFALVI Z, et al. Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study[J]. Transl Lung Cancer Res, 2021, 10(4): 1594-1607. |
[73] |
GAZIVODA V P, KANGAS-DICK A W, GREENBAUM A A, et al. Expression of PD-L1 in patients with malignant peritoneal mesothelioma: a pilot study[J]. J Surg Res, 2022, 277: 131-137.
doi: 10.1016/j.jss.2022.04.005 pmid: 35489218 |
[74] |
BUENO R, STAWISKI E W, GOLDSTEIN L D, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations[J]. Nat Genet, 2016, 48(4): 407-416.
doi: 10.1038/ng.3520 pmid: 26928227 |
[75] |
HMELJAK J, SANCHEZ-VEGA F, HOADLEY K A, et al. Integrative molecular characterization of malignant pleural mesothelioma[J]. Cancer Discov, 2018, 8(12): 1548-1565.
doi: 10.1158/2159-8290.CD-18-0804 pmid: 30322867 |
[76] | DAGOGO-JACK I, MADISON R W, LENNERZ J K, et al. Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape[J]. JCO Precis Oncol, 2022, 6: e2100422. |
[77] | LADANYI M. Implications of P16/CDKN2A deletion in pleural mesotheliomas[J]. Lung Cancer, 2005, 49(Suppl 1): S95-S98. |
[78] | ILLEI P B, RUSCH V W, ZAKOWSKI M F, et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas[J]. Clin Cancer Res, 2003, 9(6): 2108-2113. |
[79] | BRCIC L, STANG N L, GALLOB F, et al. A combination of MTAP and p16 immunohistochemistry can substitute for CDKN2A fluorescence in situ hybridization in diagnosis and prognosis of pleural mesotheliomas[J]. Arch Pathol Lab Med, 2023, 147(3): 313-322. |
[80] | SA-NGIAMWIBOOL P, HAMASAKI M, KINOSHITA Y, et al. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: a multi-institutional study[J]. Lung Cancer, 2023, 175: 27-35. |
[81] | MARTIN S D, CHEUNG S, CHURG A. Immunohistochemical demonstration of merlin/NF2 loss in mesothelioma[J]. Mod Pathol, 2023, 36(1): 100036. |
[82] | 孙蒙, 柏乾明, 赵露, 等. 荧光原位杂交检测p16基因缺失在恶性间皮瘤中的诊断价值[J]. 中华病理学杂志, 2020, 49(12): 1314-1316. |
SUN M, BAI Q M, ZHAO L, et al. Detection of p16 by fluorescence in situ hybridization and immunohistochemistry in malignant mesothelioma[J]. Chin J Pathol, 2020, 49(12): 1314-1316. | |
[83] | SMITH-HANNAH A, NAOUS R. Primary peritoneal epithelioid mesothelioma of clear cell type with a novel VHL gene mutation: a case report[J]. Hum Pathol, 2019, 83: 199-203. |
[84] | MICHAL M, KRAVTSOV O, ROSS J S, et al. Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features[J]. Genes Chromosomes Cancer, 2023, 62(5): 267-274. |
[85] | ARGANI P, LIAN D W Q, AGAIMY A, et al. Pediatric mesothelioma with ALK fusions: a molecular and pathologic study of 5 cases[J]. Am J Surg Pathol, 2021, 45(5): 653-661. |
[86] | PANAGOPOULOS I, THORSEN J, GORUNOVA L, et al.RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12)[J]. Genes Chromosomes Cancer, 2013, 52(8): 733-740. |
[87] | DERMAWAN J K, TORRENCE D, LEE C H, et al. EWSR1: : YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: report of 3 cases in support of an emerging entity[J]. Genes Chromosomes Cancer, 2022, 61(10): 592-602. |
[88] | DESMEULES P, JOUBERT P, ZHANG L, et al. A subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1/FUS-ATF1 fusions[J]. Am J Surg Pathol, 2017, 41(7): 980-988. |
[89] | WHITAKER D, HENDERSON D W, SHILKIN K B. The concept of mesothelioma in situ: implications for diagnosis and histogenesis[J]. Semin Diagn Pathol, 1992, 9(2): 151-161. |
[90] | CHURG A, HWANG H, TAN L, et al. Malignant mesothelioma in situ[J]. Histopathology, 2018, 72(6): 1033-1038. |
[91] | CHURG A, GALATEAU-SALLE F, RODEN A C, et al. Malignant mesothelioma in situ: morphologic features and clinical outcome[J]. Mod Pathol, 2020, 33(2): 297-302. |
[92] | DANUZZO F, RAVEGLIA F, SPINELLI F, et al. Pleural mesothelioma in situ: a comprehensive review[J]. Eur J Cancer Prev, 2024, 33(6): 545-551. |
[93] | SYMES E, TJOTA M, CODY B, et al. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature[J]. Histopathology, 2024, 84(3): 492-506. |
[94] | KOBAYASHI Y, YASUHARA Y, ARAI H, et al. Mesothelioma in situ of the spermatic cord arising from a patent processus vaginalis: a case report[J]. Urol J, 2020, 17(6): 671-673. |
[95] | GALATEAU-SALLE F, HAMILTON T, MACNEILL A, et al. Mesothelioma in situ mimicking well-differentiated papillary mesothelial tumor[J]. Am J Surg Pathol, 2023, 47(5): 611-617. |
[96] | HIDAKA K, TAKEDA T, KINOSHITA Y, et al. Development of mesothelioma in situ and its progression to invasive disease observed in a patient with uncontrolled pleural effusions for 15 years[J]. Pathol Int, 2020, 70(12): 1009-1014. |
[97] | KLEBE S. Progression of mesothelioma in situ to invasive disease 4 years and 10 months after initial diagnosis[J]. Pathology, 2022, 54(3): 384-386. |
[98] | NASO J R, CHURG A. Claudin-4 shows superior specificity for mesothelioma vs non-small cell lung carcinoma compared with MOC-31 and Ber-EP4[J]. Hum Pathol, 2020, 100: 10-14. |
[99] | STEVERS M, RABBAN J T, GARG K, et al. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42[J]. Mod Pathol, 2019, 32(1): 88-99. |
[100] | HUNG Y P, DONG F, TORRE M, et al. Molecular characterization of diffuse malignant peritoneal mesothelioma[J]. Mod Pathol, 2020, 33(11): 2269-2279. |
[101] |
SHAH I A, SALVATORE J R, KUMMET T, et al. Pseudomesotheliomatous carcinoma involving pleura and peritoneum: a clinicopathologic and immunohistochemical study of three cases[J]. Ann Diagn Pathol, 1999, 3(3): 148-159.
pmid: 10359850 |
[102] |
PRABHAKARAN S, HOCKING A, KIM C, et al. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas[J]. Hum Pathol, 2020, 105: 1-8.
doi: S0046-8177(20)30167-2 pmid: 32888937 |
[103] | CHURG A, LE STANG N, DACIC S, et al. Solid papillary mesothelial tumor[J]. Mod Pathol, 2022, 35(1): 69-76. |
[104] | AGAIMY A, BRCIC L, BRISKI L M, et al. NR4A3 fusions characterize a distinctive peritoneal mesothelial neoplasm of uncertain biological potential with pure adenomatoid/microcystic morphology[J]. Genes Chromosomes Cancer, 2023, 62(5): 256-266. |
[105] |
DERAKHSHAN F, IONESCU D, CHEUNG S, et al. Use of programmed death ligand-1 (PD-L1) staining to separate sarcomatoid malignant mesotheliomas from benign mesothelial reactions[J]. Arch Pathol Lab Med, 2020, 144(2): 185-188.
doi: 10.5858/arpa.2019-0370-OA pmid: 31484000 |
[106] |
MEYERHOFF R R, YANG C F, SPEICHER P J, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database[J]. J Surg Res, 2015, 196(1): 23-32.
doi: 10.1016/j.jss.2015.01.043 pmid: 25791825 |
[107] | SINGHI A D, KRASINSKAS A M, CHOUDRY H A, et al. The prognostic significance of BAP1, NF 2, and CDKN2A in malignant peritoneal mesothelioma[J]. Mod Pathol, 2016, 29(1): 14-24. |
[108] | MCGREGOR S M, MCELHERNE J, MINOR A, et al. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma[J]. Hum Pathol, 2017, 60: 86-94. |
[109] | BAUMANN F, FLORES E, NAPOLITANO A, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival[J]. Carcinogenesis, 2015, 36(1): 76-81. |
[110] |
BLUM Y, MEILLER C, QUETEL L, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications[J]. Nat Commun, 2019, 10(1): 1333.
doi: 10.1038/s41467-019-09307-6 pmid: 30902996 |
[111] |
ALCALA N, MANGIANTE L, LE-STANG N, et al. Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions[J]. EBioMedicine, 2019, 48: 191-202.
doi: S2352-3964(19)30601-2 pmid: 31648983 |
[112] | BROSSEAU S, DANEL C, SCHERPEREEL A, et al. Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the bio-MAPS cohort[J]. Clin Lung Cancer, 2019, 20(5): e564-e575. |
[113] |
SOBHANI N, ROVIELLO G, PIVETTA T, et al. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma[J]. Mol Biol Rep, 2019, 46(3): 2713-2720.
doi: 10.1007/s11033-019-04715-9 pmid: 30840203 |
[114] |
KLEBE S, JUDGE M, BRCIC L, et al. Mesothelioma in the pleura, pericardium and peritoneum: recommendations from the international collaboration on cancer reporting (ICCR)[J]. Histopathology, 2024, 84(4): 633-645.
doi: 10.1111/his.15106 pmid: 38044849 |
[115] | WITTEKIND C, GOSPODAROWICZ M, SOBIN L. TNM classification of malignant tumours, 7th edition[M]. UICC, 8th ed. Chicago: Wiley Blackwell, 2009. |
[116] | BRIERLEY J D, GOSPODAROWICZ M K, WITTEKIND C,eds. TNM classification of malignant tumours[M]. 8th ed. Chicago: Wiley Blackwell, 2016. |
[117] | RUSCH V W, CHANSKY K, NOWAK A K, et al. Malignant pleural mesothelioma. In: AJCC cancer staging manual[M]. 8th ed. Springer, 2017: 457-468. |
[118] | GILLY F N, COTTE E, BRIGAND C, et al. Quantitative prognostic indices in peritoneal carcinomatosis[J]. Eur J Surg Oncol, 2006, 32(6): 597-601. |
[119] |
SALO S A S, LANTTO E, ROBINSON E, et al. Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: national cohort study[J]. Sci Rep, 2020, 10(1): 13257.
doi: 10.1038/s41598-020-70044-8 pmid: 32764701 |
[120] |
CARBONE M. Transitional mesothelioma and artificial intelligence: do we need one more subtype? And do we need computers to identify them?[J]. J Thorac Oncol, 2020, 15(6): 884-887.
doi: S1556-0864(20)30289-6 pmid: 32471562 |
[121] |
HARTMAN D J. Applications of artificial intelligence in lung pathology[J]. Surg Pathol Clin, 2024, 17(2): 321-328.
doi: 10.1016/j.path.2023.11.013 pmid: 38692814 |
[1] | ZHAO Yihan, LI Ruochen, LIN Yansong. Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer [J]. China Oncology, 2025, 35(1): 12-20. |
[2] | WANG Renfei, LU Gaixia. The unique value and controversy of nuclear medicine molecular imaging in the evaluation of radioiodine-refractory differentiated thyroid cancer [J]. China Oncology, 2025, 35(1): 49-57. |
[3] | Society of Neuroendocrine Neoplasm of China Anti-Cancer Association. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition) [J]. China Oncology, 2025, 35(1): 85-142. |
[4] | Urologic Chinese Oncology Group. Expert consensus on early diagnosis and treatment of bladder cancer (2024 edition) [J]. China Oncology, 2024, 34(6): 607-618. |
[5] | Professional Committee on Gastric Cancer of Shanghai Anticancer Association , Professional Committee on Gastrointestinal Cancer of China Association for Promotion of Health Science and Technology . Chinese expert consensus on clinical practice of locally advanced gastric cancer invading adjacent organs (2024 edition) [J]. China Oncology, 2024, 34(5): 517-526. |
[6] | MA Fenghua, JIANG Anqi, CHEN Yiqing, XU Congjian, KANG Yu. Magnetic resonance imaging for distinguishing gastric-type endocervical adenocarcinoma from lobular endocervical glandular hyperplasia [J]. China Oncology, 2024, 34(4): 380-388. |
[7] | WANG Zhaobu, LI Xing, YU Xinmiao, JIN Feng. Important research progress in clinical practice for early breast cancer in 2023 [J]. China Oncology, 2024, 34(2): 151-160. |
[8] | Colorectal Cancer Special Committee of Shanghai Anti-Cancer Association . Shanghai plan for early screening, diagnosis and treatment of colorectal cancer (2023 edition) [J]. China Oncology, 2024, 34(1): 13-66. |
[9] | LI Tong, YANG Huijuan. Progress in diagnosis and treatment of mucinous ovarian cancer [J]. China Oncology, 2024, 34(1): 90-96. |
[10] | XU Hongtao, HUANG Xiaojuan, ZHENG Chongyang, ZHANG Zhiyuan. Development and progress of fluorescence imaging technology in diagnosis and treatment of oral cancer [J]. China Oncology, 2023, 33(9): 874-878. |
[11] | Society of Cancer of Multiple and Unknown Primary of China Anti-Cancer Association Yuguang . China Anti-Cancer Association guideline for diagnosis and treatment of cancer of multiple and unknown primaries (2023 edition) [J]. China Oncology, 2023, 33(4): 403-422. |
[12] | ZHENG Shengfeng, ZHU Yiping, YE Dingwei. Advances in basic research, clinical diagnosis and treatment of bladder cancer in 2022 [J]. China Oncology, 2023, 33(3): 201-209. |
[13] | The Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition) [J]. China Oncology, 2023, 33(12): 1092-1187. |
[14] | GUO Qinhao, YU Min, WU Xiaohua. Progress in diagnosis and treatment of gynecological tumors in 2022 [J]. China Oncology, 2023, 33(1): 14-24. |
[15] | GAO Heli, XU Jin, YU Xianjun. Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021 [J]. China Oncology, 2022, 32(9): 772-778. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd